---
title: "Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290425988.md"
description: "Nasus Pharma CEO Dan Benjamin Teleman purchased 6,550 ordinary shares at $3.10 each, totaling $20,305, according to a Form 4 filing. Following this transaction, Teleman beneficially owns 163,541 ordinary shares in the company."
datetime: "2026-06-22T11:13:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290425988.md)
  - [en](https://longbridge.com/en/news/290425988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290425988.md)
generator: "portal-rs"
---

# Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305

-   Nasus Pharma CEO Dan Benjamin Teleman bought 6,550 ordinary shares at USD 3.1 each, a Form 4 filing shows. \* Teleman reported 163,541 ordinary shares beneficially owned following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029484), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NSRX.US](https://longbridge.com/en/quote/NSRX.US.md)

## Related News & Research

- [Regenerex Pharma delays SEC quarterly filings amid added accounting and reconciliation work](https://longbridge.com/en/news/297685504.md)
- [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md)
- [Nutra Pharma says Pure Raw Supplies gains control with 62.63% voting power after Series B transfer](https://longbridge.com/en/news/297819211.md)
- [Klaria Pharma issues correction to Q2 2026 interim report](https://longbridge.com/en/news/297567497.md)
- [Abionyx Pharma sees IRIS Pharma 2026 revenue broadly stable vs 2025](https://longbridge.com/en/news/297214105.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**